X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
female (43) 43
humans (43) 43
oncology (43) 43
index medicus (42) 42
breast cancer (41) 41
breast neoplasms - drug therapy (32) 32
breast neoplasms - pathology (31) 31
middle aged (31) 31
cancer (25) 25
aged (23) 23
chemotherapy (23) 23
adult (20) 20
prognosis (20) 20
antineoplastic combined chemotherapy protocols - therapeutic use (19) 19
life sciences (19) 19
survival (18) 18
treatment outcome (15) 15
metastasis (14) 14
neoadjuvant therapy (13) 13
retrospective studies (13) 13
breast neoplasms - mortality (12) 12
neoplasm staging (12) 12
tumors (12) 12
disease-free survival (11) 11
erbb-2 protein (11) 11
follow-up studies (11) 11
aged, 80 and over (10) 10
neoadjuvant chemotherapy (10) 10
patients (10) 10
therapy (10) 10
breast neoplasms - surgery (9) 9
endocrine therapy (9) 9
metastatic breast cancer (9) 9
[ sdv.can ] life sciences [q-bio]/cancer (8) 8
care and treatment (8) 8
clinical trials (8) 8
metastases (8) 8
multivariate analysis (8) 8
survival rate (8) 8
women (8) 8
cancer therapies (7) 7
chemotherapy, adjuvant (7) 7
induction chemotherapy (7) 7
medical prognosis (7) 7
pathological response (7) 7
tamoxifen (7) 7
taxoids - administration & dosage (7) 7
trastuzumab (7) 7
adjuvant treatment (6) 6
anastrozole (6) 6
antineoplastic agents - therapeutic use (6) 6
combined modality therapy (6) 6
docetaxel (6) 6
postmenopausal women (6) 6
prospective studies (6) 6
surgery (6) 6
survival analysis (6) 6
young adult (6) 6
[sdv.can]life sciences [q-bio]/cancer (5) 5
adolescent (5) 5
analysis (5) 5
antineoplastic combined chemotherapy protocols - adverse effects (5) 5
bevacizumab (5) 5
breast neoplasms - therapy (5) 5
diagnosis (5) 5
health aspects (5) 5
medicine & public health (5) 5
preoperative chemotherapy (5) 5
receptor, erbb-2 - metabolism (5) 5
time factors (5) 5
usage (5) 5
adjuvant chemotherapy (4) 4
breast neoplasms - diagnosis (4) 4
breast neoplasms - metabolism (4) 4
clinical study (4) 4
cyclophosphamide - administration & dosage (4) 4
epidemiology (4) 4
fluorouracil - administration & dosage (4) 4
follow-up (4) 4
france (4) 4
fulvestrant (4) 4
letrozole (4) 4
male (4) 4
metaanalysis (4) 4
neoadjuvant therapy - methods (4) 4
neoplasm metastasis (4) 4
overall survival (4) 4
post-menopause (4) 4
radiation therapy (4) 4
skin and connective tissue diseases (4) 4
studies (4) 4
surgical adjuvant breast (4) 4
trial (4) 4
antimitotic agents (3) 3
antineoplastic agents (3) 3
antineoplastic agents, hormonal - therapeutic use (3) 3
antineoplastic combined chemotherapy protocols - administration & dosage (3) 3
aromatase inhibitors (3) 3
biomarkers, tumor - analysis (3) 3
breast neoplasms - chemistry (3) 3
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


PLoS Medicine, ISSN 1549-1277, 12/2016, Volume 13, Issue 12, pp. e1002201 - e1002201
Journal Article
Cancer Biology & Therapy, ISSN 1538-4047, 01/2010, Volume 9, Issue 1, pp. 8 - 14
Background. Since the improvement of chemotherapy with safe molecules is needed for better efficacy without supplementary toxicity, we investigated the... 
Binding | Proteins | Landes | Calcium | Bioscience | Biology | Cell | Cycle | Cancer | Organogenesis | Chemotherapy | Phase I | Advanced and metastatic breast cancer | Docetaxel | Clinical trial | Curcumin | Maximal tolerated dose | clinical trial | DIETARY CURCUMIN | PROSPECTIVE RANDOMIZED-TRIAL | CLINICAL-TRIAL | ANGIOGENESIS | advanced and metastatic breast cancer | ENCAPSULATED CURCUMIN | chemotherapy | CARCINOGENESIS | ONCOLOGY | docetaxel | phase I | AGENTS | TUMOR-CELL-LINES | MULTIDRUG-RESISTANCE | maximal tolerated dose | curcumin | Follow-Up Studies | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Curcumin - administration & dosage | Diarrhea - chemically induced | Feasibility Studies | Dose-Response Relationship, Drug | Neoplasm Metastasis - drug therapy | Time Factors | Leukopenia - chemically induced | Aged, 80 and over | Female | Carcinoma - pathology | Neutropenia - chemically induced | Carcinoma - drug therapy | Drug Administration Schedule | Treatment Outcome | Breast Neoplasms, Male - drug therapy | Breast Neoplasms - drug therapy | Taxoids - administration & dosage | Maximum Tolerated Dose | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Breast Neoplasms - pathology | Neoplasm Metastasis - pathology | Aged | Breast Neoplasms, Male - pathology
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2014, Volume 15, Issue 13, pp. 1493 - 1502
Journal Article
The Lancet Oncology, ISSN 1470-2045, 01/2018, Volume 19, Issue 1, pp. 87 - 100
Activation of the PI3K/AKT/mTOR pathway occurs frequently in breast cancer that is resistant to endocrine therapy. Approved mTOR inhibitors effectively inhibit... 
ACTIVATION | EVEROLIMUS | PATHWAY | RESISTANCE | ENDOCRINE THERAPY | AKT | MUTATIONS | COMBINATION | TUMORS | BKM120 | ONCOLOGY | Estradiol - analogs & derivatives | TOR Serine-Threonine Kinases - metabolism | Estrogen Receptor Antagonists - administration & dosage | Phosphatidylinositol 3-Kinase - antagonists & inhibitors | Humans | Middle Aged | Aminopyridines - adverse effects | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Receptors, Estrogen - analysis | Protein Kinase Inhibitors - adverse effects | TOR Serine-Threonine Kinases - antagonists & inhibitors | Receptors, Progesterone - analysis | Breast Neoplasms - chemistry | Time Factors | Estradiol - adverse effects | Female | Phosphatidylinositol 3-Kinase - metabolism | Morpholines - adverse effects | Aminopyridines - administration & dosage | Double-Blind Method | Biomarkers, Tumor - analysis | Morpholines - administration & dosage | Estradiol - administration & dosage | Estrogen Receptor Antagonists - adverse effects | Treatment Outcome | Breast Neoplasms - drug therapy | Disease Progression | Disease-Free Survival | Protein Kinase Inhibitors - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Breast Neoplasms - pathology | Breast Neoplasms - mortality | Aged | Receptor, ErbB-2 - analysis | Antimitotic agents | Analysis | Clinical trials | Breast cancer | Product development | Postmenopausal women | Hormones | Antineoplastic agents | Life Sciences | Cancer
Journal Article
Cancer, ISSN 0008-543X, 10/2016, Volume 122, Issue 19, pp. 3032 - 3040
BACKGROUND Treatment strategies for locally advanced breast cancer in elderly patients too frail to receive neoadjuvant chemotherapy and the introduction of... 
clinical response | hormone receptor–positive | phase 2 | breast‐conserving surgery | fulvestrant | survival | breast cancer | neoadjuvant endocrine therapy | anastrozole | postmenopausal | Postmenopausal | Anastrozole | Neoadjuvant endocrine therapy | Hormone receptor–positive | Breast cancer | Phase 2 | Clinical response | Survival | Breast-conserving surgery | Fulvestrant | INTERNATIONAL EXPERT CONSENSUS | RESPONSE RATE | TAMOXIFEN | ENDOCRINE THERAPY | SYSTEMIC THERAPY | 500 MG | CHEMOTHERAPY | WOMEN | hormone receptor-positive | ONCOLOGY | breast-conserving surgery | LETROZOLE | FIRST-LINE THERAPY | Triazoles - administration & dosage | Carcinoma, Lobular - pathology | Estradiol - analogs & derivatives | Prognosis | Follow-Up Studies | Humans | Middle Aged | Receptor, ErbB-2 - metabolism | Breast Neoplasms - metabolism | Nitriles - administration & dosage | Carcinoma, Ductal, Breast - drug therapy | Aged, 80 and over | Postmenopause | Carcinoma, Ductal, Breast - pathology | Female | Neoadjuvant Therapy | France | Carcinoma, Ductal, Breast - metabolism | Estradiol - administration & dosage | Survival Rate | Breast Neoplasms - drug therapy | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Breast Neoplasms - pathology | Aged | Carcinoma, Lobular - drug therapy | Carcinoma, Lobular - metabolism | Neoplasm Staging | Carcinoma, Lobular | Breast Neoplasms | Estradiol | Life Sciences | Triazoles | Nitriles | Carcinoma, Ductal, Breast | Antineoplastic Combined Chemotherapy Protocols | Human health and pathology | Receptor, ErbB-2 | Cancer
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2016, Volume 17, Issue 5, pp. 600 - 611
Journal Article
PLoS ONE, ISSN 1932-6203, 10/2017, Volume 12, Issue 10, p. e0185753
Journal Article
Journal Article